Generic Name and Formulations:
Sacrosidase 8500 IU/mL; oral soln.
QOL Medical, LLC
Indications for SUCRAID:
Oral replacement therapy of the genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency.
<5months: not recommended. ≥5months: ≤15kg: 8500 IU per meal or snack. >15kg: 17000 IU per meal or snack. Dilute dose with 2–4 ounces of water, milk, or infant formula. Serve cold or at room temp; do not warm up or heat liquid before or after addition of Sucraid. Give half the dose at the beginning of the meal/snack and the remainder during meal/snack.
Hypersensitivity to yeast, glycerin, papain.
Administer initial dose near facility where acute hypersensitivity reactions can be treated; discontinue if hypersensitivity occurs. Diabetes. Evaluate for dietary starch restriction. Secondary disaccharidase deficiencies. Pregnancy (Cat. C).
Do not reconstitute or consume with fruit juice; acidity reduces enzyme activity.
Abdominal pain, GI upset, constipation, insomnia, headache, nervousness, dehydration; rare: wheezing.
Soln (118mL)—2 bottles (w. measuring scoops)
Neurology Advisor Articles
- Combined Exercise Training Increases BDNF in Relapsing-Remitting MS
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Apheresis Associated With Clinical Improvement in Early Active Multiple Sclerosis
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Surgical Outcomes Associated With Trigger Site Deactivation for Migraines
- A Convenient Truth: The Problem With Seizure Under-Reporting and How to Fix It
- Incidence of Serotonin Syndrome With Co-Prescription of Triptans, Antidepressants
- Idiopathic Parkinson Disease May Increase Risk for Overactive Bladder
- Palliative Care in Movement Disorders: Recommendations for Improvement
- Cannabinoids May Be Effective as Adjunctive Treatment for Refractory Epilepsy